'Poor metabolizers' presentation slideshows

1.58k views • 68 slides

867 views • 68 slides

707 views • 46 slides

Regulatory Application of Quantitative Analysis: Impact of Biomarker Data

Regulatory Application of Quantitative Analysis: Impact of Biomarker Data. Yaning Wang, Ph.D. yaning.wang@fda.hhs.gov Team Leader, Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug Administration.

751 views • 40 slides

Biotransformation of Drugs

Biotransformation of Drugs. September 10, 2007 Frank F. Vincenzi. Learning objectives: drug biotransformation. Xenobiotic, endoplasmic reticulum & microsomes First pass effect, bioavailability Pro-drug, parent compound, metabolite (active or inactive) Lipophilicity vs. hydrophilicity

1.54k views • 36 slides

Flow of information in a drug discovery pipeline

Flow of information in a drug discovery pipeline. Bioinformatics. Computational and Combinatorial Chemisty. Predictive ADME. Absorption Distribution Metabolism Elimination. Pharmacokinetic Bioavailability. Why is the prediction of ADME parameters so important ?.

1.1k views • 34 slides

Diagnosing Addiction in Chronic Pain Patients

Diagnosing Addiction in Chronic Pain Patients. Karen Miotto, M.D. UCLA/MATRIX Addiction Medicine Service. Terminology of Abuse. Dependence - the need to maintain administration of a substance to prevent the appearance of an abstinence syndrome

524 views • 32 slides

Pharmacogenomics: The Future of Personalized Medicine

Pharmacogenomics: The Future of Personalized Medicine. Kimberly Dunbar, PA-S2 South University Khalil Khlifi, Pharm D. Candidate University of Georgia. Objectives. Provide an overview of genomics and its implications in medicine Discuss the challenges of genomics

630 views • 28 slides

Neonatal Antidepressant Effects

281 views • 27 slides

Training Our Future Colleagues and Successors

Training Our Future Colleagues and Successors. Preparing residents for 2005-2040 Much depends on the impact of: Changing demographics The Human Genome Minimally invasive procedures. Changing Demographics in the U.S. Immigration More high-risk obstetrics

399 views • 22 slides

Pharmacogenomics in Drug Development

Pharmacogenomics in Drug Development. FDA Science Board April 9, 2003 Brian B. Spear, Ph.D. Director, Pharmacogenomics Abbott Laboratories. Presentation Overview. Current application of pharmacogenomics in drug development

993 views • 21 slides

N204

N204. Cultural diversity and Medication Safety. Assumptions. Ethnic culture affects beliefs about health, illness, medications, interactions with healthcare providers, & comply with prescribed med. as well as response physiologically to med.

377 views • 19 slides

One Year Post Exclusivity Adverse Event Review: Desloratadine Pediatric Advisory Committee Meeting September 15, 2004

One Year Post Exclusivity Adverse Event Review: Desloratadine Pediatric Advisory Committee Meeting September 15, 2004. Jane Filie, MD Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration. Background Drug Information .

864 views • 16 slides